Evidence map›Paper›PMID 40955731›Full record

ArticleNephrology (Carlton, Vic.)2025

CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases.

Bhadran Bose, Simon A Carter, Mia E Abdy, Nicole Scholes-Robertson, Ieyesha Roberts, Tze Liang Goh, Vincent Lee, Emily See, Helen Coolican, Vanessa Cullen and 9 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Bhadran BoseAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0003-1539-1502
Simon A CarterAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.
Mia E AbdySydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0009-0000-8464-6711
Nicole Scholes-RobertsonSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-8260-0453
Ieyesha RobertsSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Tze Liang GohDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
Vincent LeeCentre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9400-3696
Emily SeeMelbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-4436-4319
Helen CoolicanConsumer Partner, Sydney, New South Wales, Australia.
Vanessa CullenConsumer Partner, Sydney, New South Wales, Australia.
Min JunFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1460-7535
Rathika KrishnasamyAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0001-6974-7880
Kelly LambertSchool of Medical, Indigenous and Health Sciences, The University of Wollongong, Wollongong, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5935-7328
Jonathan CraigCollege of Medicine and Health, Flinders University, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-2548-4035
Casey LightSchool of Nursing, Curtin University, Perth, Western Australia, Australia.ORCID https://orcid.org/0000-0002-3346-1490
Thu NguyenDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
Carla ScuderiKidney Health Service, Metro North Hospital and Health Service, Brisbane, Australia.ORCID https://orcid.org/0000-0002-3651-8325
David J TunnicliffeSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-3270-3475
Andrea K ViecelliAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe KDIGO 2021 Glomerular Disease Guidelines provide updated recommendations on the management of glomerular diseases (GD), with substantial advances made in diagnosis, treatment, and improvement of outcomes for people with GD.

methodsThe Caring for Australians and New Zealanders with kidney Impairment (CARI) Guidelines commentary contextualises the updated guidelines for the Australian and New Zealand setting.

resultsKidney biopsy remains central to diagnosis, with validated scoring systems available. However, genetic testing for suspected monogenic kidney disease is now accessible in Australia, enabling earlier diagnosis and management, particularly in situations where a kidney biopsy is considered high risk or contraindicated. The guideline emphasises timed urine collections for protein excretion over spot tests and we suggest the use of the CKiD u25 eGFR equation for people under 25. For IgA nephropathy (IgAN) and IgA vasculitis (IgAV), emerging therapies such as targeted-release budesonide and sparsentan demonstrate promise but await approval and public subsidy in our region. For membranous nephropathy, the guideline highlights the differences in adult and paediatric management. In nephrotic syndrome, tacrolimus is used as first-line therapy and rituximab as a second-line agent for steroid-dependent or frequently relapsing disease. Minimal change disease recommendations include glucocorticoid tapering after remission, while focal segmental glomerulosclerosis incorporates genetic classifications and advocates for next-generation sequencing.

conclusionOur commentary underscores the need for increased participation in clinical trials to validate regional applicability and improve long-term outcomes for people with GD in Australia and New Zealand. Clinical trials of new medications have led to more treatment options that are awaiting approval.

Indexed as

GlomerulonephritisKidney GlomerulusAustraliaBiopsyGlomerulonephritis, IGAHumansNew Zealandantineutrophil cytoplasmic antibody (ANCA)glomerulonephritis (GN)guidelinesIgA nephropathylupus nephritisnephrotic syndrome

Identifiers

PMID40955731
PMCPMC12439324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.